Plandai Biotechnology, Inc. is a fully reporting SEC company, publicly traded on the OTC Market under the symbol, "PLPL". As such, Business, operational and financial information on PLPL is fully transparent and available to public view.
A/S : 500 million confirmed / State of Nevada
O/S : 134.300.000 (Febr. 6th, 2015)
160.520.000 (Oct. 1st, 2015
Free Float: 66.300.000 (Febr. 6th, 2015)
? in oct. 2015
Incorporated in: NV,USA - Year of Inc.: 2012 Transfer Agent
Signature Stock Transfer, Inc., Transfer Agent, 2632 Coachlight Ct., Plano, TX, 75093, 972-612-4120
JUNE 29, 2015
Plandai Biotechnology Enters Into Agreement to Supply Phytofare to United Kingdom Distributor With First Purchase Order
GOODYEAR, AZ--(Marketwired - June 29, 2015) - Plandaí Biotechnology, Inc. (PLPL) (“Plandaí” or “the Company”), producer of the highly bioavailable green tea extract, Phytofare® Catechin Complex, today announced that it has entered into an agreement with ProTec Nutra (“ProTec”), a leading supplier of high quality ingredients to the European food and nutraceutical industry, to become the official distributor of the Company’s Phytofare® Catechin Complex in the United Kingdom (UK). ProTec has placed its first order for Plandaí’s Phytofare® Catechin Complex to fill confirmed orders that ProTec has received from its client base in the UK.
ProTec sources, develops and markets specialty ingredients and bulk products into the Functional Foods and Nutraceuticals markets in Europe with a number of manufacturing partners including Plandaí Biotechnology: www.protecnutra.com/our-partners/plandai-biotechnology.
Callum Cottrell-Duffield, Vice President of Sales and Marketing for Plandaí, said, “Having a distributor with an ethos of quality and the customer base that ProTec does, shows our intention to supply our products to companies that specialize in high quality, branded ingredients. This also reaffirms our aim to become THE supplier of highly bioavailable extracts in the marketplace. ProTec has shown a complete understanding of what we’re bringing to the market and has managed to translate this into immediate sales in the United Kingdom. I fully expect sales to increase exponentially in the coming months due to their tireless work to promote only the highest quality ingredients.”
Gary Parker is the Sales Manager for ProTec Nutra and when commenting on what separates Plandaí’s Phytofare® from other green tea extracts he said, “ProTec Nutra is committed to looking for new and innovative nutritional ingredients. A Green Tea that is ‘so different’ to the Green Tea currently dominating the health food industry is a revelation. Phytofare® quite simply ‘ticks all the boxes.’ It’s actually ‘green,’ it’s not from China, it’s backed by clinical studies and with 10x the bioavailability of a generic Green Tea, the consumer gets a product that really works and the ‘cost per dose’ is significantly lower. Beat that!”
ProTec Nutra is part of the London Pharma & Chemicals Group, Ltd. (LPC) companies (www.lpc-grp.com), a privately owned group with over 30 years of experience and offices in eight countries. LPC specializes in the supply, promotion and distribution of specialty ingredients and pharmaceutical products.
Plandai Biotechnology, Inc. Signs Agreement to Become Exclusive Supplier to USN
LOGAN, UT--(Marketwired - May 11, 2015) - Plandaí Biotechnology, Inc. (OTCQB: PLPL) (“Plandaí” or “the Company”), producer of the highly bioavailable Phytofare® catechin complex, today announced its entry into an exclusive 3 year supply agreement with USN Worldwide. Pursuant to the contract, the Company will initially sell to USN commercial amounts of Phytofare® catechin complex for USN’S South African markets. Ultimately, the parties intend to expand USN’s purchases globally into other territories in which USN operates.
USN (www.usn.co.za) was founded in South Africa in 2000, and it remains a comprehensive health and nutrition supplement brand, driving the forefront of sports nutrition globally. Rapid expansion and an increasing consumer base have been realized through a commitment to leading product innovation, the highest quality raw material suppliers globally, premium manufacturing facilities and excellent customer support on all levels. All products are formulated with the backing of extensive research and scientific findings, as well as the important clinical trials to ensure efficacy and safety. USN continues its global growth strategy, and it is now being sold in pharmacies, FMCG and specialist retailers in over 53 countries on four continents.
This agreement also allows USN to further control the input costs around production, while enhancing product efficacy by replacing the generic green tea extracts in its extensive stable of innovative and market leading products, with the clinically proven highly bioavailable Phytofare® catechin complex. This agreement gives Plandai the opportunity to cement its relationship with a long-term global customer who has a vision for growth and market expansion.
Callum Baylis-Duffield, Vice President of Sales and Marketing for Plandaí, commented, “We are extremely pleased to enter into this agreement with a company that has the remarkable reputation of USN. As a leader in sports nutrition, they understand the benefits of phyto-availability within their product line-up, as well as the need to ensure that customers are getting the maximum potential and benefit from their supplements. Such a brand can only continue its innovative streak and fantastic track record.”
Irma Botes, Head of Research and Development at USN, added, “Establishing long-term relationships with a supplier like Plandaí is an important part of ensuring that we remain at the forefront of our industry. Customers are demanding more and more from their bodies and from their nutrition supplement partner, and USN remains committed to providing the best products to the global market place. Phytofare®, by focusing on both absorption and residence in the body, using all natural botanicals, gives us a huge competitive advantage -- an advantage we’re confident our customers will notice in their performance and overall health.”
USN Founder and CEO, Albe Geldenhuys commented, "Our industry is continually progressing with respect to product innovation and scientific findings. Establishing long-term relationships with leading suppliers globally ensures that our brand embraces the innovation and the science that drives this industry, cementing our position as a global leader. This agreement is a commitment to a mutual investment that will see further product improvements in our offering this year and well into the future."
Plandai Biotechnology, Inc.'s CEO Discusses Company's Plans for 2015____________________________________
NEW YORK, NY--(Marketwired - January 09, 2015) - Plandaí Biotechnology (PLPL) recently updated shareholders on a list of accomplishments reached in 2014, so Stock Market Media Group (SMMG), a research and content development investment relations firm, spoke with Plandaí's Chief Executive Officer, Roger Duffield, to discuss Plandaí's plans for 2015.
SMMG: First and foremost, can we get your reaction to the opening of your new production facility in South Africa and what does its completion mean for Plandaí in 2015?
Roger Duffield: "Well, opening the Senteeko facility is really the culmination of over a decade of research, sacrifice, and determination. Taking the initial concept that we could produce a highly bioavailable plant extract -- at a time when no one was even looking at the importance of bioavailability for nutraceuticals -- and then seeing it through to this point, has been an amazing journey that wouldn't have happened without the help and support of countless people. I get chills every time I visit Senteeko, drive thirty minutes on logging roads through thick forests, and then pass the gates to our estate and see the vast acres of tea with this amazing jewel of a factory sitting in the middle. I'm overwhelmed, excited, relieved, and deeply humbled all at the same time."
SMMG: What is the significance of Plandaí's shift from a research and development company to a biotech that produces and sells products?
Roger Duffield: "Let me answer by first stating that Plandaí will always be a research and development company. When you look at the pharmacopeia of medicinal plants, you can see that there are hundreds of potential future research products for us. And even with just green tea catechins, we could spend a lifetime just on different human clinical trials as we explore the vast potential of this amazing plant.
"But, from a practical standpoint, now that the factory is opened, we can start generating revenues and positive cash flows. This will allow us to operate without dilution or incurring additional debt, expand our products lines, and return value to our shareholders. "Operationally, it means that we now have a whole new business model with new logistics. When you stop to think about what it takes to sell a product like Phytofare®, it requires so many moving parts working in harmony. Growing the leaf, picking it properly, manufacturing, batch testing, packaging, tracking and quality control, shipping, customs. Then you have the sales aspect, which includes marketing, trade shows, literature. It's really quite a process that I think few people fully understand."
SMMG: In 2013 Plandaí announced its entrance into the cannabis research arena, in 2014, the company secured a licensing agreement with Diego Pellicer and then obtained a consent letter from the Minister of Health in Uruguay to begin growing cannabis and producing an extract for animal testing, so what can we expect in 2015?
Roger Duffield: "Our plan at this point is to establish the cannabis growing infrastructure in Uruguay this year with an expectation of having an extract ready for testing six to nine months after it comes online. Our initial goal of having a product market-ready by the end of 2014 proved unrealistic once we determined that current U.S. laws, even in states where marijuana is legalized, prohibited us from legally acquiring cannabis, producing an extract, and then testing it inside the U.S. "Our operation in Uruguay will allow us to better control the chemical profile and then conduct our research into various neural disorders in a safe, legal, and scientifically validated manner. Also, we will be able to establish standards for dosage and chemical profile, which has so far been very limited with respect to cannabis research."
SMMG: After releasing the data in 2014 from a human clinical trial performed at North West University in South Africa that showed Plandaí's Phytofare® Catechin Complex demonstrated ten times greater bioavailability over a generic catechin extract, what is next in the on-going research at North West University?
Roger Duffield: "Starting this month, the research team at North West University in South Africa, under the supervision of the Dean's office of the Faculty of Health Sciences and the inventor of the Pheroid® delivery system, Prof. Anne Grobler, will complete the third arm of the bioavailability study. This final phase will use the same 26 human subjects, but this time the study will incorporate the addition of Pheroid® to the Phytofare® extract. "We anticipate that adding the Pheroid® delivery system will increase the overall bioavailability while also opening up the potential to use our extracts in less controlled applications such as adding Phytofare® to other ingredients including topical creams and liquids, and in environments where you are less able to control exposure to outside influences such as UV light, which kills the antioxidants."North West University will also be conducting our human weight loss clinical trial, which will test the Phytofare® versus a placebo over 90 days and involving 120 patients. This trial will also be looking at a complete blood panel so we can identify from a medical standpoint the effects of catechins on everything from blood sugar to cholesterol. The results could potentially open entirely new fields of research."
SMMG: Any closing thoughts?
Roger Duffield: "2015 promises to be a productive year for Plandaí. With the completion of the new laboratory inside the Senteeko facility, we plan to produce our first citrus extract and then test its bioavailability followed by a human clinical trial to confirm improved respiratory benefits including symptom relief for sinus, colds and the flu. And, as always, we continue to explore the medical potential of other phytonutrients and expect to test new extracts throughout the year."
For press releases please visit: www.plandaibiotech.com/press-release.html
PLANDAI BIOTECHNOLOGY at Africa
| Management Team |
Roger Duffield President, Chief Executive officer and member of the Board of Directors
Callum Baylis-Duffield Vice-President and Global Director: Marketing Sales
David Rzepnicki Chief Financial Officer and member of the Board of Directors
Tim Matula Investor Relations and member of the Board of Directors
Chief Executive Officer
Plandai Biotechnology, Inc.
1451 North 200 East, Suite 130C Logan, UT 9810
Corporate Headquarters Address: 2226 Eastlake Ave E, #156 Seattle, Washington, 98102, USA
Phone: (425) 466-0212